FDA Approves New Oral Option for Plaque Psoriasis - Top_Thought_Leaders - MDSpire

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.

  • By

  • Kathryn Wighton

  • March 18, 2026

  • 2 min

Share

Top Thought Leaders in Dermatology

Brief introduction explaining scope and methodology.

Original Source(s)

FDA Approves New Oral Option for Plaque Psoriasis

  • by Kathryn Wighton

  • March 18, 2026

Related Content

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

Imaging Improves Detection of cSCC Nodal Spread

Ultrasonography, CT may be superior, but have limited benefit in patients who are immunosuppressed. 

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial